{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:14:40Z","timestamp":1780611280294,"version":"3.54.1"},"reference-count":12,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncol Adv"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1200\/oa-25-00099","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T19:59:13Z","timestamp":1761940753000},"source":"Crossref","is-referenced-by-count":1,"title":["Alliance A022106: A Phase II\/III Trial of Nab-Paclitaxel and Gemcitabine \u00b1 Cisplatin as Second-Line Treatment for\n                    <i>BRCA1\/2<\/i>\n                    or\n                    <i>PALB2<\/i>\n                    Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct06115499","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2317-2721","authenticated-orcid":true,"given":"Erica S.","family":"Tsang","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Canada"},{"name":"University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-8832","authenticated-orcid":true,"given":"Qian","family":"Shi","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-8994","authenticated-orcid":true,"given":"Ken","family":"Olive","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Centre, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2829-355X","authenticated-orcid":true,"given":"Eric","family":"Collisson","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Centre, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-1564","authenticated-orcid":true,"given":"Jesse G.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-980X","authenticated-orcid":true,"given":"Mike","family":"Cusnir","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, Miami Beach, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-3724","authenticated-orcid":true,"given":"Rafael","family":"Winograd","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Centre, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-4508","authenticated-orcid":true,"given":"Gregory P.","family":"Botta","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Wadlow","sequence":"additional","affiliation":[{"name":"Inova Fairfax Hospital, Falls Church, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8244-2704","authenticated-orcid":true,"given":"Ardaman","family":"Shergill","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-0898","authenticated-orcid":true,"given":"Jeffrey A.","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":true,"given":"Eileen M.","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Centre, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-1753","authenticated-orcid":true,"given":"Andrew H.","family":"Ko","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0418"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4291"},{"key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"PR12","DOI":"10.1158\/1538-7445.MOUSEMODELS17-PR12","article-title":"Selective lethality of cisplatin in pancreatic cancer is dependent on mitotic functions of BRCA2","volume":"78","author":"Orelli B","year":"2018","unstructured":"Orelli B, Mauer HC, Palmero CF, et al: Selective lethality of cisplatin in pancreatic cancer is dependent on mitotic functions of BRCA2. Cancer Res 78:PR12, 2018. (abstract)","journal-title":"Cancer Res"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02931"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaoncol.2019.3394","article-title":"Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b\/2 pilot clinical trial","volume":"6","author":"Jameson GS","year":"2020","unstructured":"Jameson GS, Borazanci E, Babiker HM, et al: Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b\/2 pilot clinical trial. JAMA Oncol 6:125-132, 2020","journal-title":"JAMA Oncol"},{"key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"e7412","DOI":"10.1002\/cam4.7412","article-title":"Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer","volume":"13","author":"Jameson GS","year":"2024","unstructured":"Jameson GS, Hosein PJ, Pierce E, et al: Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer. Cancer Med 13:e7412, 2024","journal-title":"Cancer Med"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01383"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834016676011"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3229"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T19:59:14Z","timestamp":1761940754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1200\/OA-25-00099"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00099","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"e2500099"}}